Bromide

Bromide

SCHEMBL8469764

Br.C1CCC2=NCCCN2CC1

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 6/20 0.37
SIGMAR1 known ✓ Q99720 1/20 0.33
INMT O95050 4/20 0.95
USP2 O75604 2/20 0.95
NOS3 P29474 3/20 0.34
NOS1 P29475 3/20 0.34
NOS2 P35228 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALDH1A1 P00352 2/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL14761484 1.00 INMT (0.95) INMTUSP2ACHENOS3NOS1
Bromide SCHEMBL29980319 0.98 INMT (0.91) INMTUSP2ACHENOS3NOS1
SCHEMBL3047 0.98 INMT (1.00) INMTUSP2ACHENOS3NOS1
SCHEMBL10601682 0.98 INMT (1.00) INMTUSP2ACHENOS3NOS1
SCHEMBL17417853 0.98 INMT (1.00) INMTUSP2ACHENOS3NOS1
SCHEMBL16583523 0.98 INMT (1.00) INMTUSP2ACHENOS3NOS1
SCHEMBL2734323 0.98 INMT (1.00) INMTUSP2ACHENOS3NOS1
Bromide SCHEMBL18093523 0.96 INMT (0.88) INMTUSP2ACHENOS3NOS1
Bromide SCHEMBL29732962 0.96 INMT (0.88) INMTUSP2ACHENOS3NOS1
Iodide SCHEMBL23365018 0.95 INMT (0.95) INMTUSP2ACHENOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022212727-A1 METHOD OF CONVERSION OF LACTIC ACID AND POLYLACTIC ACID TO ACRYLIC ACID OR ACRYLATES IN LIQUID PHASE NITTO DENKO CORPORATION (JP) 2022-10-06 WO claimed
EP-3583088-B1 SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS PROVIVI INC (US) 2025-09-10 EP disclosed
CN-110603240-B Synthesis of pheromones and related substances via olefin metathesis 普罗维维公司 2022-11-15 CN disclosed
CN-114478510-B Preparation method of nifuratel 盐城凯利药业有限公司 2022-11-01 CN disclosed
WO-2022212727-A1 METHOD OF CONVERSION OF LACTIC ACID AND POLYLACTIC ACID TO ACRYLIC ACID OR ACRYLATES IN LIQUID PHASE NITTO DENKO CORPORATION (JP) 2022-10-06 WO disclosed
CN-114478510-A Preparation method of nifuratel 盐城凯利药业有限公司 2022-05-13 CN disclosed
US-11155505-B2 Synthesis of pheromones and related materials via olefin metathesis PROVIVI, INC. (US) 2021-10-26 US disclosed
US-20200039900-A1 SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS PROVIVI, INC. (US) 2020-02-06 US disclosed
WO-1999028355-A1 FUNCTIONAL POLYMERS WITH CARBON-LINKED FUNCTIONAL GROUPS ACTIVE MATERIALS INC. (CA) 1999-06-10 WO disclosed
EP-0634456-B1 VULCANIZABLE FLUOROELASTOMER COMPOSITION DU PONT (US) 1998-11-18 EP disclosed
US-5508355-A CONTAINING A POLYOL VULCANIZER, ALIPHATIC AMINE AND CATIONIC ACCELERATOR; IMPROVED MOLD RELEASE, WORKABILITY IN INJECTIONMOLDING E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-04-16 US disclosed
EP-0634456-A1 VULCANIZABLE FLUOROELASTOMER COMPOSITION E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039900-A1 SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS OSBPL8, CYP51A1, ERG28 ACHE 748/4885SIGMAR1 1685/4885INMT 2427/4885
US-11155505-B2 Synthesis of pheromones and related materials via olefin metathesis OSBPL8, CYP51A1, ERG28 ACHE 748/4885SIGMAR1 1685/4885INMT 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.